Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-11-19 Sale | 2024-11-20 8:37 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 7,785 | $1.01 | $7,863 | 243,019 (Direct) | View |
2024-08-19 Sale | 2024-08-20 9:15 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 6,866 | $1.28 | $8,788 | 250,804 (Direct) | View |
2024-05-17 Sale | 2024-05-20 9:13 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 7,355 | $1.75 | $12,871 | 257,670 (Direct) | View |
2024-02-20 Sale | 2024-02-22 8:19 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,014 | $0.68 | $6,130 | 265,025 (Direct) | View |
2023-11-17 Sale | 2023-11-20 9:02 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,646 | $0.49 | $4,727 | 274,039 (Direct) | View |
2023-08-16 Sale | 2023-08-17 8:08 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,703 | $0.78 | $7,568 | 283,685 (Direct) | View |
2023-05-16 Sale | 2023-05-17 8:29 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 9,791 | $0.72 | $7,050 | 293,388 (Direct) | View |
2023-02-16 Sale | 2023-02-17 9:00 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 10,484 | $3 | $31,452 | 303,179 (Direct) | View |
2022-11-16 Sale | 2022-11-18 6:05 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 13,460 | $3.57 | $48,052 | 313,663 (Direct) | View |
2022-08-18 Sale | 2022-08-19 6:27 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 73,716 | $4.65 | $342,779 | 327,123 (Direct) | View |
2022-08-16 Sale | 2022-08-17 7:41 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 10,560 | $4.76 | $50,266 | 670,839 (Direct) | View |
2022-05-16 Sale | 2022-05-17 9:40 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 21,673 | $3.95 | $85,608 | 276,399 (Direct) | View |
2022-02-16 Sale | 2022-02-18 6:20 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 10,912 | $10.95 | $119,486 | 274,122 (Direct) | View |
2021-11-16 Sale | 2021-11-17 6:11 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 20,869 | $13.16 | $274,636 | 232,084 (Direct) | View |
2021-08-16 Sale | 2021-08-18 7:04 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 7,662 | $13.83 | $105,965 | 212,803 (Direct) | View |
2021-05-17 Sale | 2021-05-19 7:08 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 31,111 | $18.3 | $569,331 | 235,065 (Direct) | View |
2021-02-16 Sale | 2021-02-18 7:07 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 24,141 | $22.37 | $540,034 | 266,176 (Direct) | View |
2020-11-23 Sale | 2020-11-25 6:09 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 16,380 | $16.4 | $268,632 | 250,317 (Direct) | View |
2020-11-16 Sale | 2020-11-18 7:08 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 29,618 | $16.93 | $501,433 | 266,697 (Direct) | View |
2020-08-17 Sale | 2020-08-19 6:41 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 26,200 | $19.67 | $515,354 | 296,315 (Direct) | View |
2020-05-18 Sale | 2020-05-20 6:33 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 4,558 | $22.51 | $102,601 | 322,515 (Direct) | View |
2020-02-18 Sale | 2020-02-20 6:39 pm | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 4,774 | $22.35 | $106,699 | 327,073 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-12-13 Option Award | 2023-12-15 6:07 pm | N/A 2031-12-12 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 250,000 | $0 | 250,000 (Direct) | View |
2022-08-15 Option Award | 2022-08-17 7:41 pm | N/A 2030-08-14 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 405,000 | $0 | 670,839 (Direct) | View |
2022-05-15 Option Award | 2022-05-17 9:40 pm | N/A N/A | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 23,950 | $0 | 276,399 (Direct) | View |
2021-12-16 Option Award | 2021-12-20 8:28 pm | N/A 2029-12-15 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 146,950 | $0 | 379,034 (Direct) | View |
2021-11-15 Option Award | 2021-11-17 6:11 pm | N/A N/A | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 40,150 | $0 | 232,084 (Direct) | View |
2021-10-12 Option Award | 2021-10-14 9:10 pm | N/A 2027-12-11 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 71,550 | $0 | 71,550 (Direct) | View |
2020-12-18 Option Award | 2020-12-22 6:53 pm | N/A 2028-12-17 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 111,500 | $0 | 361,817 (Direct) | View |
2019-12-12 Option Award | 2019-12-16 9:37 pm | N/A 2027-12-11 | NEKTAR THERAPEUTICS | NKTR | Zalevsky Jonathan Chief R&D Officer | 131,800 | $0 | 423,497 (Direct) | View |